Trial Profile
A Combination Phase I Open Label Dose Escalation Study of Concomitant Administration of BIBW 2992 with BIBF 1120 in Patients with Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Sep 2009
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Nintedanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 26 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 May 2009 Planned number of patients changed from 24 to 28 as reported by ClinicalTrials.gov.
- 01 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.